← All trials
NCT03393702
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 9, 2017
- Primary completion
- Dec 30, 2019
- Completion date
- Dec 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute for Tuberculosis and Lung Diseases, PolandLead sponsor
- National Institute for Tuberculosis and Lung Diseases, PolandReponsible party - principal investigator
- National Institute for Tuberculosis and Lung Diseases, PolandStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.